FRIENDS of CANCER RESEARCH

Artificial Intelligence-Driven Response Evaluation Criteria in Solid Tumors Project

The ai.RECIST Project

Tumor Scans Support an Understanding of Treatment Response

FRIENDS of CANCER RESEARCH



Radiological Baseline Scan | **Tumor Measurement** | **Treatment** | **Radiological Surveillance Scan** | **Tumor Measurement** | **Assess Response**

Traditionally in clinical trials, radiologists measure tumors at the local sites and later, the measurement is confirmed by a blinded independent central review (BICR).

There is potential to incorporate AI tools that measure tumors to streamline this process.

New Project: ai.RECIST

QUESTION: Can AI-based imaging tools improve tumor measurement?

Phase 1: Evaluating the Feasibility of AI Tools for Supporting RECIST Measurements in Clinical Trials

- Determine AI tool capabilities.
- Align on image characteristics and metadata.
- Compare AI tools and human readers using a common dataset to assess variability.

Phase 2: Refining RECIST Using AI-Based Imaging Tools

- Consider alternative approaches for measuring tumor burden (e.g., kinetics, metabolomics).
- Establish a standardized approach for integrating AI-based imaging tools into clinical trials.

This project is kicking off now – stay tuned for updates!